Manufacturer
PFIZER MANUFACTURING BELGIUM NV,
Contents
Medroxyprogesterone acetate
Indication
Contraception, endometriosis, menopausal vasomotor symptoms; hormonally-dependent, recurrent breast cancer in post-menopausal women. Adjunctive &/or palliative treatment of recurrent &/or metastatic endometrial or renal carcinoma
Instruction
Injectable suspensions should be shaken well before use. IM Contraception 150 mg every 3 mth. Endometriosis 50 mg wkly or 100 mg every 2 wk for at least 6 mth. Menopausal vasomotor symptoms 150 mg every 12 wk. Recurrent &/or metastatic endometrial or renal cancer Initially 400-1,000 mg wkly then maintain at 400 mg mthly. Hormonally-dependent, recurrent breast cancer in postmenopausal women Initially 500 mg daily for 28 days then maintain at 500 mg twice wkly.
Drug interaction
Medroxyprogesterone acetate (MPA) is metabolized in-vitro primarily by hydroxylation via the CYP3A4. Specific drug-drug interaction studies evaluating the clinical effects with CYP3A4 inducers or inhibitors on MPA have not been conducted and therefore, the clinical effects of CYP3A4 inducers or inhibitors are unknown.
Malaysia
